Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning! Today we take a look at what the FDA’s embrace of flexibility might mean for gene therapy development and see the Supreme Court take a new case that could have real implications for brand-name drugmakers and generics companies. Plus, a good amount of breaking biotech news.
GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal
From STAT’s Andrew Joseph: GSK said this morning that it would buy RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies. GSK is paying $58 per share for the South San Francisco biotech, a roughly 65% premium on Rapt’s closing price on Friday.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply